Expression of tumour pyruvate kinase type M2 on pancreatic cancer and it's clinicopathologic connection

LI Jing,HUANG Liang,ZHOU Fei-guo,YAN Jian-jun,LIU Cai-feng,YAN Yi-qun

DOI: https://doi.org/10.3877/cma.j.issn.1674-0785.2011.19.018

2011-01-01

Abstract:Objective To investigate the expression of tumour pyruvate kinase type M2 (tumour M2-PK)on pancreatic cancer and the connection between the expression of tumour M2-PK and the clinicopathologic manifestations.Methods 35 cases were selected from patients who were conducted operations in our hospital from January 2004 to June 2007 and were pathologically diagnosed pancreatic cancer.Sections were stained immunohistochemically with antibody to tumour M2-PK.Positive stain was defined as yellow stain in the cytoplasm.Intensity of stain was divided into no stain,poor stain and strong stain,and proportion of cells with positive stain was divided into 0,<30%,30%-60%,>60% and 100% by the semiquantitative method.Results All 35 cases showed 100% staining,of which 7 were weakly stained while other 28 were strongly stained.No differences were detected among different pathological classifications,clinical stages,lymph node involvement or distal metastasis.The proportions of cells with strong stain were 72.7%,83.3% and 83.3% in the well,moderately and poorly differentiated specimen respectively,and were both 80% in the specimen with and without lymph node or distant metastasis,and were 85.7%,76.5%,83.3% and 80.0% in the specimen of clinical stage Ⅰ,Ⅱ,Ⅲ and Ⅳ respectively.None of the differences was statistical significant.Conclusions Tumour M2-PK was highly expressed in pancreatic cancer,but there was no association between the expression of tumour M2-PK and the clinicopathologic manifestations.